Skip to main content

Table 4 Association of CHEK2 H371Y with pathological response according to neoadjuvant treatment regimens

From: Association between CHEK2 H371Y mutation and response to neoadjuvant chemotherapy in women with breast cancer

Chemotherapy

N

non-pCR, n (%)

pCR, n (%)

P-value

Anthracycline

859

  

0.35

Non-carriers

841

687 (81.7)

154 (18.3)

 

Carriers

18

13 (72.2)

5 (27.8)

 

Anthracycline-taxane

882

  

0.032

Non-carriers

872

700 (80.3)

172 (19.7)

 

Carriers

10

5 (50.0)

5 (50.0)

 

Taxane

593

  

0.71

Non-carriers

582

461 (79.2)

121 (20.8)

 

Carriers

11

8 (72.7)

3 (27.3)

 
  1. pCR, pathologic complete response.